Join
Live feed
·
PRReleasevia Quantisnow
Aligos Therapeutics Inc. logo

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

ByQuantisnow·Wall Street's wire, on your screen.
ALGS· Aligos Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALGS (Aligos Therapeutics Inc.) and more on Quantisnow.